Current Report Filing (8-k)
August 19 2020 - 4:07PM
Edgar (US Regulatory)
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: August 17, 2020
(Date of earliest event reported)
ENTASIS
THERAPEUTICS HOLDINGS INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-38670
|
82-4592913
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
35 Gatehouse Drive
Waltham, MA 02451
|
|
|
(Principal Executive Office)
|
|
|
|
|
|
Telephone Number: (781) 810-0120
|
|
|
|
|
|
Not Applicable
|
|
Former name or former address, if changed since last report
|
Securities registered or to be
registered pursuant to Section 12(b) of the Act.
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
ETTX
|
The Nasdaq Stock Market, LLC
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act
of 1934. Emerging growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On August 17, 2010, Entasis Therapeutics Holdings Inc. (the
“Company”) accepted the resignation of Eric Kimble, our Chief Commercial Officer, effective September 4, 2020.
Mr. Kimble has indicated to the Company that his resignation
is not the result of any dispute or disagreement with the Company.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ENTASIS THERAPEUTICS HOLDINGS INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Elizabeth M. Keiley
|
|
|
General Counsel
|
Dated: August 19, 2020
|
|
|
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Apr 2023 to Apr 2024